Epizyme, Inc.
Jul 31, 2017

Epizyme Announces Date of Second Quarter Financial Results and Presentation at Wedbush PacGrow Healthcare Conference

CAMBRIDGE, Mass., July 31, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management will host a conference call in conjunction with the announcement of its second quarter 2017 financial results and present at the 2017 Wedbush PacGrow Healthcare Conference. Details of both events are as follows:

Replays of both webcasts will be available in the investor section of the company's website at http://www.epizyme.com for 60 days following the call and presentation.

About Epizyme, Inc.
Epizyme, Inc. is a clinical-stage biopharmaceutical company committed to rewriting cancer treatment through novel epigenetic medicines. Epizyme is broadly developing its lead product candidate, tazemetostat, a first-in-class EZH2 inhibitor, with studies underway in both solid tumors and hematological malignancies as a monotherapy and combination therapy and in relapsed and front-line disease. Using the Company's proprietary platform, Epizyme has pioneered the identification and development of small molecule inhibitors of chromatin modifying proteins (CMPs), such as tazemetostat. CMPs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of CMPs, which can allow cancer cells to grow and proliferate. By focusing on the genetic drivers of cancers, Epizyme's science seeks to match targeted medicines with the specific patients that need it. For more information, visit www.epizyme.com and connect with us on Twitter at @EpizymeRx.

Contacts:

Cheya Pope, Epizyme, Inc.

media@epizyme.com

617-229-7561



Monique Allaire, THRUST IR

monique@thrustir.com

(617) 895-9511

Primary Logo

Source: Epizyme, Inc.

News Provided by Acquire Media